Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now later-stage tilt small index

Edentulism: later-stage trial registry

3 of 5 indexed Edentulism trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #3,391 of 28,707 conditions by registered trial count.

5 US clinical trials · 3 currently recruiting · #3,391 of 28,707 conditions by registered trial count

Edentulism: 5 US clinical trials tracked, 3 recruiting.

Edentulism is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Dentsply International, running 1 of these trials.

Enrollment posture brief

Registry condition edentulism

OPEN 3 | RECR 60% | LATE 1 | EARLY 0 | RANK #3391 | SPON 1

Nearest open-share peer: Acute Kidney Injury (AKI) (60% recruiting · 5 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Edentulism (this)60%
Open-enrollment share among volume-matched conditions near Edentulism

Edentulism lists 3 open slots (60% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Edentulism on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Edentulism is recruiting above its size-band peers.

    3 of 5 indexed trials (60%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Edentulism research.

    Dentsply International accounts for 1 of 5 trials (20%). 5 distinct sponsors appear on at least one study for this condition label.

  3. Most Edentulism trials plan to enrol fewer than 100 people.

    Median target enrolment is 30 among the 5 trials that report a genuine target (sentinel values excluded). 4 of those (80%) plan for fewer than 100 participants.

  4. Edentulism research is mostly interventional.

    4 interventional and 1 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 41

Phase Distribution

PhaseTrial count
Phase 4 1

Named interventions

Most-linked intervention names on Edentulism records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Biomet 3i Prevail Implants Device
1 trials
Ankylos Implants Device
1 trials
ASTRA TECH Implant System, OsseoSpeed™ Device
1 trials
dental implant Device
1 trials
Platelet-rich fibrin (PRF) Procedure
1 trials
Placement of dental implants Procedure
1 trials

US sites by state

Facility locations filed on Edentulism trials. A trial with sites in several states counts in each.

Pennsylvania 2 trials
New York 1 trials
Nebraska 1 trials
Florida 1 trials
Colorado 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Edentulism page

5 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Edentulism condition card totals 5 registered trials; most-linked intervention Biomet 3i Prevail Implants; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.